NVCHI
EGRX

New Vernon Capital Holdings II’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

New Vernon Capital Holdings II’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,918
Closed -$202K – 49
2018
Q3 		$202K Hold
2,918
– – 0.21% 47
2018
Q2 		$221K Buy
+2,918
New +$184K 0.24% 40

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

New Vernon Capital Holdings II's EGRX Position: Q4 2018 in Review

New Vernon Capital Holdings II sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 2,918 shares — an estimated $202K sold.

New Vernon Capital Holdings II first reported a position in EGRX in Q2 2018 and held it in 2 quarters. The position peaked at $221K in Q2 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

  • New Vernon Capital Holdings II reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • New Vernon Capital Holdings II sold 2,918 Eagle Pharmaceuticals, Inc. shares in Q4 2018, an estimated $202K.
  • New Vernon Capital Holdings II first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
  • New Vernon Capital Holdings II's Eagle Pharmaceuticals, Inc. position peaked at $221K in Q2 2018.
  • 182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on New Vernon Capital Holdings II's 13F filing for Q4 2018, filed 13 Feb 2019.